Dexcom (DXCM): Director sold ~$54K
Kyle Malady, Director at Dexcom, sold ~$54K of Dexcom shares.
- ~$54K
- Approx. value · 667 sh @ $80.86
- 23K
- Holds after · shares reported
- Traded
- Sep 5, 2025
- Filed
- Sep 9, 2025
What stands out in this filing
- The sale was 2.9% of the shares this insider held before it; the filing reports 22,667 shares afterwards.
- 667 shares at an average of $80.86 each, as reported on the form.
- Footnote references a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jul 15, 2025Insider · 2 peopleInsiders: 3 sales (~$277K)
- Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM Android App Model/Catalog Number: SW12299 Software Version: version 2.8.…
- Jul 24, 2025FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ Android CGM App Model/Catalog Number: SW14245 Software Version: versions…
- Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: versions 2.8…
- Jul 24, 2025FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.4…
- Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: version 2.8.0 an…
- Jul 28, 2025InsiderOfficer sold ~$130K of DXCM shares in the open market
- Aug 15, 2025Insider · 2 peopleInsiders: 3 sales (~$263K)
- Aug 27, 2025Layoff notice · 6290-6350 Sequence Drive San Diego CA 92121Layoff notice filed in CA: 319 employees
- Aug 28, 2025FDARecall: Brand Name: Dexcom G6 Continuous Glucose Monitoring System Product Name: Dexcom G6 and G6 Pro Android US CGM App Model/Catalog Number: SW11678 Software Version…
- Sep 2, 2025InsiderOfficer sold ~$358K of DXCM shares in the open market
- Sep 4, 2025InsiderOfficer sold ~$117K of DXCM shares in the open market
- Sep 5, 2025 · this disclosureInsiderDirector sold ~$54K of DXCM shares in the open market
What came next
- Sep 14, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 14, 2025, Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board of DexCom, Inc. (“Dexcom” or the “Company”) is taking a temporary medical leave of absence.”
- Oct 24, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 24, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to ten directors and appointed Dr. Euan Ashley as a director, effective immediately.”
- Oct 27, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Prime v. DexCom, Inc.
- Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
- Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 12.6%
- Nov 10, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Oakland County Employees Retirement System v. DexCom, Inc.
- Nov 10, 2025Insider · 2 peopleInsiders: 2 purchases (~$1.0M), 1 sale (~$218K)
- Nov 12, 2025InsiderDirector sold ~$59K of DXCM shares in the open market
- Nov 14, 2025InsiderDirector sold ~$172K of DXCM shares in the open market
- Nov 18, 2025FDAFDA device clearance: Dexcom Smart Basal
- Nov 25, 2025Court · District Court, S.D. CaliforniaSecurities lawsuit filed: Boston Retirement System v. Dexcom, Inc.
- Dec 17, 2025FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
- Dec 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026, following Kevin R. Sayer’s resignation, effective as of such date.”
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Dexcom
For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.
Other recent filings by Kyle Malady, Director
- SEC Form 4 at Verizon (VZ)Nov 18, 2026
- SEC Form 4 at Verizon (VZ)Nov 12, 2026
- SEC Form 4 at Verizon (VZ)Nov 4, 2026
- SEC Form 4 at Verizon (VZ)Oct 28, 2026
- SEC Form 4 at Verizon (VZ)Oct 21, 2026
The full history of Kyle Malady, Director is on the profile page.
How this filing works
Explore the data
Common questions
Which Dexcom (DXCM) insider traded, and how much?
Kyle Malady, Director at Dexcom, sold ~$54K of Dexcom shares. 667 shares at $80.86.
When did it happen, and when was it made public?
Traded: Sep 5, 2025. Filed: Sep 9, 2025. That is 4 days between the two dates.
What stands out in this filing?
The sale was 2.9% of the shares this insider held before it; the filing reports 22,667 shares afterwards. 667 shares at an average of $80.86 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Dexcom recently?
For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DXCM page.
Does this mean DXCM stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Dexcom
- SEC Form 4Nov 18, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 16, 2026
- SEC Form 4Oct 28, 2026
- SEC Form 144Oct 27, 2026
- SEC Form 4Oct 19, 2026
Everything OQRO holds on this company is on its DXCM page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
